More about our sector?

this is your place

Cultural Resistance… Who are the Real Enablers?

Cultural Resistance… Who are the Real Enablers?


Advanced analytics technologies in the pharmaceutical industry are accessible now more than ever and regulators have slowly become more accepting to these kinds of advances.  The introduction of machine learning, artificial intelligence, and big data technologies are disrupting our industry, and it’s time we change our mindset.  People are the real enablers of the paradigm shift and if we continue this pattern of cultural resistance, pharmaceutical companies cannot continue accelerating and will not remain competitive in the growing pharmaceutical market.

Technology in place

From the processing of big data to the kinds of cloud computing architectures (serverless and SaaS), the industry is evolving.  Technology has made it possible for most companies to afford remote computing power akin to NASA’s servers.  Additionally, tools running artificial intelligence (AI) models are becoming much more accessible.  Companies continue gaining access to these kinds of technologies and it is time they start leveraging them.  Why are companies still using basic statistics and only working with a few process variables?   


Regulators are becoming more open minded

Up to now, the fear of regulatory exposure was used as an excuse for companies to stay conservative and away from implementing new technologies.  But as the industry continues to shift, this is coming to end. There has been a real mindset shift in how agencies incorporate new technologies into their standards and guidelines. A recent example is from the European Pharmacopoeia, where they established artificial neural networks and support vector machines as chemometric methods applied to analytical data.

Also, the MHRA (Medicines and Healthcare products Regulatory Agency) established a GxP Data Integrity Guidance for cloud providers including Software-as-a-Service, Platform-as-a-Service, and Infrastructure-as-a-Service.

And the FDA (Food and Drugs Administration) has incorporated a cloud technology into their Emerging Technology Team recognizing that it will influence how quality systems will be assessed by FDA.



The need for change

There is a clear trend in the decrease in margins while regulatory pressures continue to increase. Additionally, there are no more blockbusters and the increase in personalized medicine will require more flexible production requirements. Taking into consideration all of these factors, most companies are not using 70% of their manufacturing data.  It’s clear that there is huge room for improvement.

There is also an increasing number of FDA Warning Letters for data integrity issues that reflect a clear lack of process knowledge and data management skills.

People, People, and People

There are several factors important in enabling Pharma 4.0 but one of the most crucial components in the paradigm shift is the people.  The workforce is used to working in such regulated and protected markets surviving in their comfort zone.  Nowadays, technologies allow us to work with big data in the cloud while ensuring data integrity and cloud technologies. 

At this point, we know the reason for changing, we have the technologies and tools in place and regulators aligned.  So why is the pharma industry so slow to adopt these new technologies? Because of the mindset of people. Pharma 4.0 will continue to stay as an industry hype in the marketing departments until we have a real mindset shift.

Melissa Villalobos

Sales and Marketing Coordinator

Bigfinite and NNE Partnership

Bigfinite and NNE announced a strategic partner program agreement to collaborate around accelerating digital transformation within manufacturing operations at the world's leading pharmaceutical and biotech manufacturers. 

Where are Pharma Companies in the Age of Artificial Intelligence?

They say good things come to those who wait; we say good things come to those who wait but only the things left by the visionaries before them.  The pharmaceutical industry has long been known to lag in the adoption of new technology due to strong regulations. Even though regulators have recently begun to open up to several new ‘big data’ or pharma 4.0 technologies - the question remains, if pharma companies are doing the same?  In 2016, the European Pharmacopoeia 9.0 in Chapter 5.21 announced that neural networks (NN) and support vector machines (SVM) are valid chemometric techniques for processing analytical data sets. 

Data Scientist 4.0 – Bridging the World of Manufacturing and Data

Since the announcement of the 4th Industrial Revolution in 2011, multitudes of emerging technologies have transpired around “Industry 4.0”. Technologies such as digital twins, Industrial Internet of Things (IIoT), and cyber-physical systems have come into the scene as core elements, providing the necessary ingredients for a paradigm shift in manufacturing. Technologies around predictive analytics and artificial intelligence are pioneering new approaches with many use cases including predictive maintenance, autonomous process optimization, and pattern recognition - used to identify potential failures in real-time. Because of this, data science is becoming an invaluable discipline for our industry in order to transform information into knowledge.

Making the Conversation Real – What To Expect From The AI Manufacturing Team At Xavier University

Our co-founder and R&D Director Toni Manzano is a team lead for Xavier University AI in Manufacturing Team where, with the help of FDA officials and industry professionals, they address how the power of AI can be used to optimize manufacturing operations in the life sciences industry.

Taking Smart Manufacturing “Back to The Future”

What does the future look like in a smart factory in the pharma or biotech industry? We believe a smart factory is a digitally transformed facility and operation that is reaping the benefits of increased productivity. In fact, some experts predict an order of magnitude productivity gain! It is this productivity gain we need to aim and think about when talking digital transformation, it is the vision and the clear long-term goal. And yes, it is super important because with a clear goal it is easier to prioritize which technology to try first and where or what to digitally transform first, in other words, the strategy.

AWS re:Invent 2018 is Here!  Are You Ready?

Bigfinite is excited to announce that we will be attending the 2018 AWS re:Invent!  For the past three years, we have attended the annual conference and every year this event has continued to gain tremendous growth and take the city by storm.

Cultural Resistance… Who are the Real Enablers?

Advanced analytics technologies in the pharmaceutical industry are accessible now more than ever and regulators have slowly become more accepting of these kinds of advances.  The introduction of machine learning, artificial intelligence, and big data technologies are disrupting our industry, and it’s time we change our mindset.

Gartner Selects Bigfinite as “2018 Cool Vendor for Life Sciences”

We are excited to share that Bigfinite was selected as a 2018 Gartner Cool Vendor for Life Sciences - the only company solely focused on GxP manufacturing intelligence and analytics!

A story about adoption – Pharma 4.0 at the world’s largest insulin manufacturers

Pharma 4.0 is a popular topic in this years ISPE Annual Meeting event in Philly and currently of great interest in the industry as a whole.

Pharma 4.0 is here – we need to understand the compliance implications of big data and AI

With Pharma 4.0 comes a paradigm shift in many aspects. We in the pharma industry know all too well that every move we make needs to consider compliance with regulation - it's in everything that we do. Yet we can’t ignore the promise that these new technologies come with while at the same time speculating about the regulatory aspects. Although it may seem overwhelming right now, we must change the way we think.  New technologies such as big data, artificial intelligence, machine learning, and deep learning offer unprecedented analysis of real-time data and can even predict trends in processes, operations, and quality. You probably have heard this many times before, but it is truer this time than before.